secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001104659-24-041462
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Judge lifts YUTREPIA injunction; Tyvaso PH-ILD exclusivity expires March 31
---------------------------------------------------------------------------

- March 28: Judge Andrews set aside August 2022 injunction; FDA can now approve YUTREPIA NDA.
- March 29: Judge Bates denied United Therapeutics' motion for TRO/preliminary injunction against FDA approval.
- March 31: Regulatory exclusivity for Tyvaso in PH-ILD expired; FDA can act on YUTREPIA amended NDA.
- United Therapeutics filed appeal and new lawsuits, but none currently block YUTREPIA launch.
- Liquidia commercial team ready to launch for PAH and PH-ILD upon FDA final approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924041462/0001104659-24-041462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924041462/tm2410292d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-041462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer